Switching to NOACs in frail elderly patients with atrial fibrillation increases bleeding risk

Switching vitamin K antagonist (VKA) treatment to a non-vitamin K antagonist oral anticoagulant (NOAC) in frail elderly patients with atrial fibrillation is associated with more bleeding complications compared to continuing VKA treatment.

Researchers validate first-ever AI biomarker for ADT benefit in prostate cancer

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.

June 30, 2023

Ablation more effective than medical therapy in patients with end-stage heart failure, study shows

Atrial fibrillation ablation is associated with lower rates of death, urgent heart transplantation or left ventricular assist device (LVAD) implantation compared with medical therapy in

August 28, 2023

MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million – Biotech Investments

MorphoSys AG / Key word(s): Capital Increase Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7

December 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.